Abstract

This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The purpose of this study is to learn about relationships between lifestyle characteristics and cardiovascular risk factors, body fat distribution, metabolic syndrome and certain substances in the blood such as fats and factors that may cause blood clotting problems and inflammation in people who are long-term liver transplant recipients. Recruitment for the study will include males and females who received their liver transplants after age 21 and are less than 69 years of age. This is a minimal risk study that will require an overnight visit to the GCRC where blood samples will be taken and a questionnaire will be filled out regarding current diet.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000065-46
Application #
7717045
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2007-12-01
Project End
2008-11-30
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
46
Fiscal Year
2008
Total Cost
$2,654
Indirect Cost

  Institution

Name
Virginia Commonwealth University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298

  Publications

Holkova, Beata; Yazbeck, Victor; Kmieciak, Maciej et al. (2017) A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leuk Lymphoma 58:1349-1357
Corey, Kathleen E; Vuppalanchi, Raj; Vos, Miriam et al. (2015) Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 60:360-7
Eaton, J E; Juran, B D; Atkinson, E J et al. (2015) A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. Aliment Pharmacol Ther 41:980-90
Worthington Jr, Everett L; Berry, Jack W; Hook, Joshua N et al. (2015) Forgiveness-reconciliation and communication-conflict-resolution interventions versus retested controls in early married couples. J Couns Psychol 62:14-27
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent et al. (2014) Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res 20:5652-62
Noureddin, Mazen; Yates, Katherine P; Vaughn, Ivana A et al. (2013) Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 58:1644-54
Lo, D J; Anderson, D J; Weaver, T A et al. (2013) Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 13:320-8
Poklepovic, Andrew; Youssefian, Leena E; Youseffian, Leena et al. (2013) Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Invest New Drugs 31:937-42
Holkova, Beata; Supko, Jeffrey G; Ames, Matthew M et al. (2013) A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res 19:1873-83
Lo, D J; Farris, A B; Song, M et al. (2013) Inhibition of ?v?6 promotes acute renal allograft rejection in nonhuman primates. Am J Transplant 13:3085-93

Showing the most recent 10 out of 367 publications